Want to see TSE:PREV full AI Analyst Report?
PREV Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume42.00K
Average Volume (3M)170.07K
Market Cap
C$12.76M
Enterprise ValueC$13.85M
Total Cash (Recent Filing)C$35.66K
Total Debt (Recent Filing)C$4.84M
Price to Earnings (P/E)―
Beta-0.48
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding638,186,950
10 Day Avg. Volume165,545
30 Day Avg. Volume170,073
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Therapeutic And Delivery PipelineA portfolio spanning therapeutic applications and drug-delivery technologies gives PreveCeutical multiple avenues for future product development and intellectual-property monetization. If programs advance, this breadth could support licensing or partnering opportunities beyond a single candidate or indication.
Asset Base ImprovementAn increase in total assets versus 2024 provides a limited sign that the company has expanded its resource base. This does not offset the equity deficit or leverage, but it may provide some additional platform for continuing research and pursuing commercialization over the medium term.
Cash-burn VisibilityCash usage broadly tracking reported losses makes the company’s funding requirement more understandable than a situation where cash burn materially exceeds accounting losses. While still negative, this alignment can improve the visibility of near-term capital needs and operating discipline.
Bears Say
No Demonstrated Commercial RevenueZero reported revenue across the available periods indicates that the research portfolio has not yet translated into a demonstrated commercial business. Without product sales or other recurring operating revenue, future progress remains dependent on successful development, partnering, or intellectual-property monetization.
Negative Equity And High LeverageNegative stockholders’ equity combined with debt materially exceeding the asset base signals a weak capital structure and limited financial flexibility. This increases dependence on external financing and can constrain investment in research, while raising the risk that future funding may be dilutive or difficult to obtain.
Persistent Cash BurnPersistent negative operating and free cash flow means the company is not funding its activities internally and must continue consuming capital. The latest deterioration in free cash flow suggests funding needs may be rising, which can delay development priorities and increase reliance on external financing.
PreveCeutical Medical News
PREV FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.05 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is C$12.76M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Nov 19, 2026 which is in 19 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
PreveCeutical Medical Inc released its earnings results on Aug 28, 2026. The company reported -C$0.002 earnings per share for the quarter.
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 638,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
PreveCeutical Medical Inc reported an EPS of -C$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in TSE:PREV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―